Joseph Guarino, MD
Cardiovascular Disease · Toms River, NJNPI 1558479436
Payments from drug & device makers
Across 450 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Abbott$2K
- Johnson & Johnson$2K
- Amgen$945
- Novartis$870
- plus $3K from 31 others
What the payments were for
- Food & beverage$13,729100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $2,792 |
| E.r. Squibb & Sons, L.L.C. | 50 | $2,293 |
| Abbott | 28 | $1,984 |
| Johnson & Johnson | 71 | $1,718 |
| Amgen | 24 | $945 |
| Novartis | 77 | $870 |
| Boston Scientific | 26 | $440 |
| Amarin Pharma, Inc. | 15 | $390 |
| Pfizer | 20 | $371 |
| Merck | 19 | $267 |
| Boehringer Ingelheim | 14 | $224 |
| Irhythm Technologies, Inc. | 8 | $191 |
| Shockwave Medical, Inc | 1 | $171 |
| Bayer | 4 | $154 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| Medtronic | 2 | $103 |
| Catheter Precision Inc. | 1 | $103 |
| Stereotaxis Inc | 1 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Scpharmaceuticals Inc. | 2 | $50 |
| Novo Nordisk | 3 | $44 |
| Edwards Lifesciences | 2 | $40 |
| Cvrx, Inc. | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Gilead | 2 | $28 |
| Preventice Services, LLC | 2 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Biotronik Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
| Acarix USA Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,427
- CAMZYOS$941
- XARELTO$846
- ELIQUIS$691
- Repatha$575
- LOKELMA$233
- Vascepa$223
- MitraClip$213
- AMPLATZER AMULET$206
- Vascular Lithotripsy$171
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$131
- Quadra Assura CRT Defibrillator$128
- Otezla$125
- NURTEC ODT$125
- Confirm Rx$120
- WAINUA$119
- Kerendia$111
- Watchman$110
How this compares
$13,754 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 271 | $332,540 |
| XareltoRivaroxaban | 227 | $284,237 |
| EntrestoSacubitril/Valsartan | 79 | $99,203 |
| Repatha SureclickEvolocumab | 45 | $42,057 |
| FarxigaDapagliflozin Propanediol | 34 | $31,186 |
| BrilintaTicagrelor | 28 | $20,454 |
| VascepaIcosapent Ethyl | 32 | $14,352 |
| PlavixClopidogrel Bisulfate | 24 | $12,148 |
| Icosapent Ethyl | 30 | $11,734 |
| Metoprolol Succinate | 640 | $10,500 |
| XanaxAlprazolam | 12 | $9,532 |
| LipitorAtorvastatin Calcium | 13 | $9,020 |
| Ranolazine ErRanolazine | 80 | $8,950 |
| Repatha SyringeEvolocumab | 13 | $7,772 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $7,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lipitor | $371 | $341,560284 claims |
| Johnson & JohnsonXarelto | $1,718 | $284,237227 claims |
| NovartisEntresto | $870 | $99,20379 claims |
| AstraZenecaFarxiga, Brilinta | $2,792 | $51,64062 claims |
| Sanofi-aventis U.S. LLCPlavix | $14 | $12,14824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Toms River
- Lance BergerToms River$132K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.